The AstraZeneca PLC ADR AZN slid 0.68% to $66.94 Thursday, on what proved to be an all-around poor trading session for the stock market, with the NASDAQ Composite Index COMP falling 0.66% to 19,902.84 ...

AstraZeneca (AZN) and Merck (MRK) reported positive long-term survival data for their drug Lynparza in the treatment of ...

Shares of AstraZeneca PLC AZN inched up 0.28% to £105.68 Thursday, on what proved to be an all-around great trading session for the stock market, with the FTSE 100 Index UKX rising 0.12% to 8,311.76.

In a report released today, Steve Scala from TD Cowen maintained a Buy rating on AstraZeneca (AZN – Research Report), with a price target of ...

NEW YORK, NY / ACCESSWIRE / December 11, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of AstraZeneca PLC ...

AstraZeneca and Merck report Lynparza's significant survival benefits in high-risk breast cancer and Keytruda combo results ...

LinkedIn likes have landed drugmakers in trouble once again. AstraZeneca—a repeat offender—and GSK were the subjects of the ...

Trying to break from the decade-old practice of using BTK inhibitors indefinitely to treat blood cancer, AstraZeneca has ...

An AstraZeneca Pharmaceuticals PLC subsidiary faces a lawsuit from a former director who said she was subjected to sexist treatment from male colleagues and retaliation after filing a report with HR ...

When looking ahead to 2025, Cramer noted a significant lack of consensus about future rate cuts. He pointed to Fed funds ...

British drugmaker AstraZeneca has appointed a new China head, replacing a former executive who has been detained by ...

AstraZeneca (AZN) said the FDA has accepted its supplemental Biologics License Application for Imfinzi for Priority Review for the treatment of muscle-invasive bladder cancer.